FDA approves medical device using shape memory technology

August 6, 2018, Lawrence Livermore National Laboratory
The Food and Drug Administration approved the use of IMPEDE, a medical device used to treat bleeding abnormalities by deliberately blocking blood flow, which incorporates expanding shape memory polymer technology partly developed at Lawrence Livermore National Laboratory. Credit: Todd Landsman/Shape Memory Medical

The Food and Drug Administration has approved the use of a medical device in humans for deliberately blocking blood flow to treat bleeding abnormalities or other conditions, a procedure known as embolization. The device integrates expanding shape memory polymer technology that was partly developed at Lawrence Livermore National Laboratory (LLNL).

The FDA recently granted Shape Memory Medical, a company founded by former LLNL scientist Duncan Maitland, with clearance for its IMPEDE embolization plug, designed to block or reduce flow in peripheral vasculature. The can be "programmed" into a particular shape, made thin enough to fit in a catheter and expand to its former shape when exposed to stress or heat. The advantages of IMPEDE, Maitland said, include simple delivery through any diagnostic catheter, ease of navigation through twisted and quick, stable embolization without compromising the vessel wall.

Much of the technology behind the device was developed at LLNL, and later at Texas A&M University, through multiple grants and investments from the Department of Energy's Office of Science, National Institutes of Health and Laboratory Directed Research and Development, dating back to the 1990s. Over the years, it has involved the work of dozens of Lab scientists, Ph.D.s and graduate students who researched materials and designed biomedical devices that could better occlude blood clots and help prevent hemorrhagic stroke. In 2003, the work expanded to include devices that could cut blood supply to certain areas of the peripheral vasculature for treatment of aneurysms. LLNL has numerous patents on the technology.

Approval clears major hurdle for shape memory devices

Researchers said the device has immense potential to replace current embolization technology, which generally employs metal coils that occasionally tear through walls of the blood vessels and lead to further complications such as hemorrhaging. Shape memory foams can be made thin enough to be inserted into blood vessels and arteries, and once in place, expand either on a time-release basis or when heated by the blood to seal up vessels and arteries and allow for healing tissue to develop.

"It's an entry point for the technology," said LLNL staff researcher Thomas Wilson, who has been working on materials for biomedical devices for more than a decade. "This (FDA approval) is a tremendous hurdle, and what's been achieved will open the doors to other shape memory devices. This is the baby step. It's a huge satisfaction to actually see this come to fruition and see it help people."

The LLNL team, working under a series of NIH grants that began in 2003, tested materials that would not only be thin enough to fit through a catheter but would have enough attenuation or "bounce-back" properties to allow it to expand quickly to completely fill the vein or artery. Maitland, who spent more than a dozen years at LLNL, left the Lab to become a professor at Texas A&M University. Under a cooperative research and development agreement (CRADA) with the Lab, development of the devices continued at Texas A&M. Maitland founded his company as Shape Memory Therapeutics Inc. and completed animal testing to support application in humans. The company changed its name and is headquartered in Santa Clara, California.

"Approximately 20 years ago, Tom and I envisioned a new way to occlude vessels," Maitland said. "Seeing IMPEDE used to treat patients that would be otherwise untreatable with current technologies is an engineer's dream outcome. I am very grateful to the many people that have participated in and supported this work."

'Decades' of development at LLNL

LLNL scientist Jennifer Rodriguez started her work on memory polymers for medical devices as an undergraduate at the Lab in 2005, leaving several years later to work with Maitland at Texas A&M on a Ph.D., and returned to Livermore as a postdoc in 2014. Because the polymer materials used in the foam are low density and don't absorb X-rays, Rodriguez worked on ensuring the devices would show up in medical imaging and engineered the foam material with channels so blood could pass through them and allow the body to begin the healing process.

"It's taken decades to get where they are, from developing the polymers to designing devices to creating the devices," Rodriguez said. "It's rewarding to have worked on something that now has the potential to help somebody and advance health care."

LLNL engineer Ward Small began working on the materials in 2003, fabricating catheter-based devices and discovering how to get them to actuate or expand under laser light. The biggest challenge, he said, was to achieve enough expansion and coming up with a way to detach it from its wire guide, deliver it precisely to the affected area and have it stay in place.

"The goal from the beginning was to actually see this come to fruition," Small said. "We were hopeful, but it took a long time. It's awesome that something that started here is on its way."

Explore further: Shape memory foam embolization system deployed in Europe now cleared for U.S. markets

Related Stories

Shape memory foam embolization system deployed in Europe now cleared for U.S. markets

July 20, 2018
Shape Memory Medical recently announced FDA clearance for U.S. marketing of their IMPEDE Embolization Plug, a technology funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and created to block ...

Researcher provides a more effective method for treating aneurysms

April 24, 2017
What started as a whiteboard concept nearly 20 years ago by Dr. Duncan Maitland, the Stewart & Stevenson Professor I in the Department of Biomedical Engineering at Texas A&M University, could soon turn into a revolutionary ...

Going beyond 3-D printing to add a new dimension for additive manufacturing

August 24, 2016
A team of Lawrence Livermore National Laboratory researchers has demonstrated the 3-D printing of shape-shifting structures that can fold or unfold to reshape themselves when exposed to heat or electricity. The micro-architected ...

Researchers use special foams to treat aneurysms

June 11, 2013
An innovative method for treating potentially fatal brain aneurysms by filling them with foam-like plastics is a step closer to clinical trials after demonstrating an ability to promote healing at unprecedented levels, says ...

Recommended for you

Study: What patients really think about opioid vs non-opioid medications for chronic pain

August 14, 2018
Prescriptions of opioids for chronic pain has increased dramatically since the 1990s in spite of their known harms. Despite a shortage of scientific studies on the long-term effectiveness of opioids such as morphine, oxycodone ...

Doctors nudged by overdose letter prescribe fewer opioids

August 9, 2018
In a novel experiment, doctors got a letter from the medical examiner's office telling them of their patient's fatal overdose. The response: They started prescribing fewer opioids.

Benzodiazepine and related drug prescriptions have increased among young people in Sweden

August 7, 2018
The prevalence rate of prescriptions for benzodiazepines and benzodiazepine-related drugs (BZD)—medications used to treat anxiety, insomnia, epilepsy and other neuropsychiatric conditions—increased by 22% between 2006 ...

Unwise opioids for wisdom teeth: Study shows link to long-term use in teens and young adults

August 7, 2018
Getting wisdom teeth removed may be a rite of passage for many teens and young adults, but the opioid painkiller prescriptions that many of them receive could set them on a path to long-term opioid use, a new study finds.

Behavioral nudges lead to striking drop in prescriptions of potent antipsychotic

August 1, 2018
A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel (quetiapine), an antipsychotic with potentially harmful side effects in the elderly, significantly ...

US opioid use not declined, despite focus on abuse and awareness of risk

August 1, 2018
Use of prescription opioids in the United States has not substantially declined over the last decade, despite increased attention to opioid abuse and awareness of their risks, finds a study published by The BMJ today.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.